MEDP vs. ROIV: Medpace vs. Roivant Sciences Stock Comparison

November 11, 2026

How do Medpace (MEDP) and Roivant Sciences (ROIV) stack up? This page sets them side by side across company profile, performance and risk, profitability, growth, financial strength, dividends, and valuation, with selected fundamentals also measured against each stock's industry-group peers.

Company Profile

Medpace (MEDP) and Roivant Sciences (ROIV) both fall under the Pharmaceuticals, Biotechnology & Life Sciences industry group, but MEDP is classified in Life Sciences Tools & Services while ROIV is classified in Biotechnology.

Company profile comparison for Medpace (MEDP) and Roivant Sciences (ROIV)
Profile Item	MEDP	ROIV
Name	Medpace Holdings, Inc.	Roivant Sciences Ltd.
Country/Region	United States	United Kingdom
GICS Sector	Health Care	Health Care
GICS Industry Group	Pharmaceuticals, Biotechnology & Life Sciences	Pharmaceuticals, Biotechnology & Life Sciences
GICS Industry	Life Sciences Tools & Services	Biotechnology
GICS Sub-Industry	Life Sciences Tools & Services	Biotechnology
Market Capitalization	18.27 billion USD	28.08 billion USD
Currency	USD	USD
Exchange	Nasdaq	Nasdaq
Listing Date	August 11, 2016	December 8, 2020
Security Type	Common Stock	Common Stock

Price Performance

Cumulative Growth

MEDP

ROIV

GSPC

Medpace (MEDP) vs. Roivant Sciences (ROIV), with S&P 500 (GSPC) for reference: Growth of a $10,000 investment over the past five years. Adjusted for dividends and splits.

Trailing Returns

Loading price history…

Trailing total returns for Medpace (MEDP) and Roivant Sciences (ROIV). Returns over one year are annualized.

Calendar-Year Returns

Loading price history…

Calendar-year total returns for Medpace (MEDP) and Roivant Sciences (ROIV). Each bar is that year's total return, measured year-end to year-end.

Performance Metrics

Price performance metrics for Medpace (MEDP) and Roivant Sciences (ROIV)
Metric	MEDP	ROIV
Total Return (1Y)	13.29%	96.75%
Total Return (3Y, Annualized)	35.26%	68.04%
Total Return (5Y, Annualized)	24.49%	36.73%

Risk Profile

Drawdown History

MEDP

ROIV

GSPC

Medpace (MEDP) vs. Roivant Sciences (ROIV), with S&P 500 (GSPC) for reference: Drawdown from the running peak over the past five years. Each line shows the decline from its prior peak; 0% marks a new high.

Return Distribution

Loading price history…

Distribution of monthly total returns for Medpace (MEDP) and Roivant Sciences (ROIV). Each bar is the share of months whose return fell in that 5% bucket.

Risk Metrics

Risk profile metrics for Medpace (MEDP) and Roivant Sciences (ROIV)
Metric	MEDP	ROIV
Volatility (1Y, Annualized)	44.16%	47.99%
Beta (5Y)	1.10	1.17
Max Drawdown (5Y)	-42.87%	-79.22%
Avg. Volume (3M)	258.39K	7.82M

Risk-Adjusted Performance

Risk-Return Positioning

MEDP and ROIV are plotted by 1-year volatility (risk) and 1-year return. The dashed Capital Allocation Line runs from the risk-free rate through the shared industry median.

Risk-Adjusted Metrics

Risk-adjusted metrics for Medpace (MEDP) and Roivant Sciences (ROIV)
Metric	MEDP	ROIV
Sharpe Ratio (1Y)	0.20	1.93
Sortino Ratio (1Y)	0.26	4.03

Profitability

ROE (TTM)

Roivant Sciences (ROIV) reports a negative ROE of -8.52%; negative ROE can reflect losses or negative shareholders’ equity, so it is harder to read as capital efficiency. Meanwhile Medpace (MEDP) reports 117.88%, ranking against industry peers normally.

MEDP

Pharmaceuticals, Biotechnology & Life Sciences industry group

117.88%

MEDP: 117.88%
Max: 109.18%
Q3: 6.23%
Median: -26.66%
Q1: -64.05%
Min: -167.77%

ROIV

Pharmaceuticals, Biotechnology & Life Sciences industry group

-8.52%

Max: 109.18%
Q3: 6.23%
ROIV: -8.52%
Median: -26.66%
Q1: -64.05%
Min: -167.77%

Medpace (MEDP) vs. Roivant Sciences (ROIV): A comparison of their ROE against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Net Margin (TTM)

Medpace (MEDP) at 18.24% converts revenue to bottom-line profit above its industry’s benchmark range, while Roivant Sciences (ROIV) at 0.00% keeps roughly the typical share for its industry.

MEDP

Pharmaceuticals, Biotechnology & Life Sciences industry group

18.24%

MEDP: 18.24%
Max: 18.05%
Q3: 4.78%
Median: 0.00%
Q1: -4.14%
Min: -17.05%

ROIV

Pharmaceuticals, Biotechnology & Life Sciences industry group

0.00%

Max: 18.05%
Q3: 4.78%
ROIV: 0.00%
Median: 0.00%
Q1: -4.14%
Min: -17.05%

Medpace (MEDP) vs. Roivant Sciences (ROIV): A comparison of their net margin against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Operating Margin (TTM)

Roivant Sciences (ROIV) reports a negative operating margin of -25,408.11%, usually indicating that operating costs exceeded revenue at the operating-income line. Meanwhile Medpace (MEDP) reports 23.12%, ranking against industry peers normally.

MEDP

Pharmaceuticals, Biotechnology & Life Sciences industry group

23.12%

Max: 83.12%
MEDP: 23.12%
Q3: 14.77%
Median: 0.00%
Q1: -78.82%
Min: -207.40%

ROIV

Pharmaceuticals, Biotechnology & Life Sciences industry group

-25,408.11%

Max: 83.12%
Q3: 14.77%
Median: 0.00%
Q1: -78.82%
Min: -207.40%
ROIV: -25,408.11%

Medpace (MEDP) vs. Roivant Sciences (ROIV): A comparison of their operating margin against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Profitability Metrics

Profitability metrics for Medpace (MEDP) and Roivant Sciences (ROIV)
Metric	MEDP	ROIV
ROE (TTM)	117.88%	-8.52%
ROA (TTM)	18.71%	-16.28%
Net Margin (TTM)	18.24%	0.00%
Operating Margin (TTM)	23.12%	-25,408.11%
Gross Margin (TTM)	72.24%	0.00%

Growth

Revenue Growth

Medpace (MEDP) at 19.97% is around its peer norm for revenue growth, while Roivant Sciences (ROIV) at -71.57% drops into the bottom quartile, signaling weaker demand or pricing momentum.

Medpace (MEDP) vs. Roivant Sciences (ROIV): A comparison of their Revenue Growth across different time periods.

EPS Growth

Only one side can be read here: Medpace (MEDP) reports EPS growth of 20.98%, ranked against its industry; Roivant Sciences (ROIV) has no EPS growth figure this period.

Medpace (MEDP) vs. Roivant Sciences (ROIV): A comparison of their EPS Growth across different time periods.

Growth Metrics

Growth metrics for Medpace (MEDP) and Roivant Sciences (ROIV)
Metric	MEDP	ROIV
Revenue Growth (YoY)	19.97%	-71.57%
Revenue Growth (3Y CAGR)	20.12%	-36.01%
EPS Growth (YoY)	20.98%	--
EPS Growth (3Y CAGR)	28.04%	--

Financial Strength

Current Ratio (MRQ)

Roivant Sciences (ROIV) at 16.72 carries current ratio above its industry’s typical mid-range, while Medpace (MEDP) at 0.83 runs in the tighter-liquidity quartile — different working-capital profiles, both worth examining.

MEDP

Pharmaceuticals, Biotechnology & Life Sciences industry group

0.83

Max: 25.13
Q3: 12.13
Median: 5.52
Q1: 2.47
MEDP: 0.83
Min: 0.10

ROIV

Pharmaceuticals, Biotechnology & Life Sciences industry group

16.72

Max: 25.13
ROIV: 16.72
Q3: 12.13
Median: 5.52
Q1: 2.47
Min: 0.10

Medpace (MEDP) vs. Roivant Sciences (ROIV): A comparison of their current ratio against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Debt / Equity (MRQ)

Both Medpace (MEDP) at 0.29 and Roivant Sciences (ROIV) at 0.02 fund their balance sheets with roughly industry-typical debt-to-equity mixes.

MEDP

Pharmaceuticals, Biotechnology & Life Sciences industry group

0.29

Max: 1.42
Q3: 0.65
MEDP: 0.29
Median: 0.15
Q1: 0.02
Min: 0.00

ROIV

Pharmaceuticals, Biotechnology & Life Sciences industry group

0.02

Max: 1.42
Q3: 0.65
Median: 0.15
ROIV: 0.02
Q1: 0.02
Min: 0.00

Medpace (MEDP) vs. Roivant Sciences (ROIV): A comparison of their debt-to-equity ratio against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Financial Strength Metrics

Financial strength metrics for Medpace (MEDP) and Roivant Sciences (ROIV)
Metric	MEDP	ROIV
Current Ratio (MRQ)	0.83	16.72
Debt / Equity (MRQ)	0.29	0.02
Net Debt / EBITDA	-0.84	--

Dividends

Dividend Yield (TTM)

Neither Medpace (MEDP) nor Roivant Sciences (ROIV) pays a dividend this period — they may reinvest, use buybacks, or simply not return cash through dividends.

MEDP

Pharmaceuticals, Biotechnology & Life Sciences industry group

0.00%

MEDP: 0.00%
Max: 0.00%
Q3: 0.00%
Median: 0.00%
Q1: 0.00%
Min: 0.00%

ROIV

Pharmaceuticals, Biotechnology & Life Sciences industry group

0.00%

ROIV: 0.00%
Max: 0.00%
Q3: 0.00%
Median: 0.00%
Q1: 0.00%
Min: 0.00%

Medpace (MEDP) vs. Roivant Sciences (ROIV): A comparison of their dividend yield against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Dividend Payout Ratio (TTM)

Neither Medpace (MEDP) nor Roivant Sciences (ROIV) pays a dividend this period — they may reinvest, use buybacks, or simply not return cash through dividends.

MEDP

Pharmaceuticals, Biotechnology & Life Sciences industry group

0.00%

MEDP: 0.00%
Max: 0.00%
Q3: 0.00%
Median: 0.00%
Q1: 0.00%
Min: 0.00%

ROIV

Pharmaceuticals, Biotechnology & Life Sciences industry group

0.00%

ROIV: 0.00%
Max: 0.00%
Q3: 0.00%
Median: 0.00%
Q1: 0.00%
Min: 0.00%

Medpace (MEDP) vs. Roivant Sciences (ROIV): A comparison of their payout ratio against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Dividend Metrics

Dividend metrics for Medpace (MEDP) and Roivant Sciences (ROIV)
Metric	MEDP	ROIV
Dividend Yield (TTM)	0.00%	0.00%
Dividend Payout Ratio (TTM)	0.00%	0.00%

Valuation

P/E Ratio (TTM)

An earnings multiple is available for just one side: Medpace (MEDP) trades at 36.26 times trailing earnings, ranked against its peers, while Roivant Sciences (ROIV) has no P/E ratio this period.

MEDP

Pharmaceuticals, Biotechnology & Life Sciences industry group

36.26

Max: 85.34
Q3: 43.46
MEDP: 36.26
Median: 26.69
Q1: 13.30
Min: 0.07

ROIV

Pharmaceuticals, Biotechnology & Life Sciences industry group

Max: 85.34
Q3: 43.46
Median: 26.69
Q1: 13.30
Min: 0.07
ROIV: --

Medpace (MEDP) vs. Roivant Sciences (ROIV): ROIV does not report P/E ratio, so it has no value marker; MEDP is benchmarked against the Pharmaceuticals, Biotechnology & Life Sciences industry group.

P/S Ratio (TTM)

Medpace (MEDP) at 6.44 prices around its industry’s typical P/S ratio, while Roivant Sciences (ROIV) at 3,728.61 clears its benchmark range — ROIV looks notably rich on sales.

MEDP

Pharmaceuticals, Biotechnology & Life Sciences industry group

6.44

Max: 58.18
Q3: 25.77
Median: 7.30
MEDP: 6.44
Q1: 3.01
Min: 0.01

ROIV

Pharmaceuticals, Biotechnology & Life Sciences industry group

3,728.61

ROIV: 3,728.61
Max: 58.18
Q3: 25.77
Median: 7.30
Q1: 3.01
Min: 0.01

Medpace (MEDP) vs. Roivant Sciences (ROIV): A comparison of their P/S ratio against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

P/B Ratio (MRQ)

Both look rich against book: Roivant Sciences (ROIV) at 6.64 sits in the upper P/B ratio quartile, and Medpace (MEDP) at 31.23 prices even higher, above its industry range.

MEDP

Pharmaceuticals, Biotechnology & Life Sciences industry group

31.23

MEDP: 31.23
Max: 13.53
Q3: 6.54
Median: 3.25
Q1: 1.69
Min: -5.59

ROIV

Pharmaceuticals, Biotechnology & Life Sciences industry group

6.64

Max: 13.53
ROIV: 6.64
Q3: 6.54
Median: 3.25
Q1: 1.69
Min: -5.59

Medpace (MEDP) vs. Roivant Sciences (ROIV): A comparison of their P/B ratio against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Valuation Metrics

Valuation metrics for Medpace (MEDP) and Roivant Sciences (ROIV)
Metric	MEDP	ROIV
P/E Ratio (TTM)	36.26	--
P/S Ratio (TTM)	6.44	3,728.61
P/B Ratio (MRQ)	31.23	6.64
Free Cash Flow Yield (TTM)	2.72%	-3.98%